Detalles de la búsqueda
1.
Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients.
J Oncol Pharm Pract
; 28(5): 1130-1139, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34111994
2.
Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.
J Oncol Pharm Pract
; 26(5): 1070-1079, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31631810
3.
Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients.
Eur J Haematol
; 103(5): 500-509, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31444815
4.
Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review.
Clinicoecon Outcomes Res
; 16: 447-459, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38831921
5.
Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH).
Pharmacoecon Open
; 8(1): 133-146, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37980316
6.
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
J Manag Care Spec Pharm
; 30(6): 541-548, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38824632
7.
Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States.
Pulm Circ
; 14(2): e12326, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38623409
8.
Hospitalization Among Pulmonary Arterial Hypertension Patients With and Without Connective Tissue Disease Comorbidities Prescribed Oral Selexipag.
Rheumatol Ther
; 10(3): 741-756, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36959524
9.
Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension.
Adv Ther
; 40(5): 2481-2492, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37024760
10.
Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
J Med Econ
; 26(1): 644-655, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086091
11.
Hospitalization-related costs associated with oral agents targeting the prostacyclin pathway for pulmonary arterial hypertension.
J Med Econ
; 26(1): 1349-1355, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37800591
12.
Impact of selexipag use within 12 months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study.
Clin Respir J
; 17(12): 1209-1222, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37804160
13.
A claims-based, machine-learning algorithm to identify patients with pulmonary arterial hypertension.
Pulm Circ
; 13(2): e12237, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37287599
14.
Impact of the COVID-19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension-specific therapy in the United States of America: An observational study.
Pulm Circ
; 13(3): e12283, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37701141
15.
Economic burden of illness among patients with pulmonary arterial hypertension (PAH) associated with connective tissue disorders (CTD).
Pulm Circ
; 13(2): e12218, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37051491
16.
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder-Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis.
Adv Ther
; 40(11): 5037-5054, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37728697
17.
Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository.
Pulm Circ
; 13(3): e12258, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37427090
18.
The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.
J Manag Care Spec Pharm
; 28(6): 608-616, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35621726
19.
Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims data.
Curr Med Res Opin
; 38(6): 1019-1030, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35243952
20.
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Clin Lymphoma Myeloma Leuk
; 22(11): e959-e971, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973891